乌苯美司片联合SOX方案治疗晚期胃癌的效果及对T淋巴细胞水平、预后影响

Efficacy of Ubenimex Tablets Combined with SOX Regimen in the Treatment of Advanced Gastric Cancer and Its Influence on T Lymphocyte Level and Prognosis

目的:探讨乌苯美司片联合SOX方案(奥沙利铂+替吉奥)治疗晚期胃癌的效果及对T淋巴细胞水平、预后的影响。方法:对龙岩市第二医院2020年6月-2021年6月收治的127例晚期胃癌患者实施回顾性分析,将63例应用SOX方案治疗的患者纳入SOX组,64例在SOX方案基础上联合乌苯美司片治疗的患者则归为联合组。两组连续治疗3个月后,比较其T淋巴细胞水平,包括CD3^(+)、CD4^(+)、CD8^(+)及CD56^(+),并测定两组血管生长因子(VEGF)、癌胚抗原(CEA)与糖类抗原199(CA199),对两组治疗效果开展评估,同时对治疗前后两组的血小板、血红蛋白及白细胞计数进行对比,记录治疗期间患者不良反应。结果:治疗后,联合组CD3^(+)、CD4^(+)及CD56^(+)均比SOX组高,而CD8^(+)则较SOX组低(P<0.05);相较于SOX组,联合组的VEGF、CEA与CA199水平均更低(P<0.05);联合组疾病控制率为76.56%,明显较SOX组的57.14%高(P<0.05);联合组血小板、血红蛋白及白细胞计数均比SOX组高(P<0.05);治疗期间联合组不良反应发生率为9.38%,较SOX组的26.98%低(P<0.05)。结论:给予晚期胃癌患者乌苯美司片与SOX的联合治疗可有效改善其免疫功能和血清肿瘤标志物水平,能有效控制疾病进展,同时有助于减少化疗产生的毒副反应,不良反应发生风险较低,可改善预后,因此能作为临床治疗晚期胃癌的优选方案。

Objective:To investigate the efficacy of Ubenimex Tablets combined with SOX regimen(Oxaliplatin+Tegafur,Gimeracil and Oteracil Potassium) in the treatment of advanced gastric cancer and its effect on T lymphocyte level and prognosis.Method:A retrospective analysis was performed on 127 patients with advanced gastric cancer admitted to the Second Hospital of Longyan from June 2020 to June 2021.A total of 63patients treated with SOX regimen were included in the SOX group,and 64 patients treated with Ubenimex Tablets on the basis of SOX regimen were included in the combined group.After 3 months of continuous treatment,T lymphocyte levels of the two groups were compared,including CD3,CD4,CD8and CD56,and vascular growth factor (VEGF),carcinoembryonic antigen (CEA) and carbohydrate antigen 199 (CA199) were measured in the two groups,the therapeutic effect of the two groups were evaluated.At the same time,platelet,hemoglobin and white blood cell count of the two groups before and after treatment were compared,and adverse reactions of patients during treatment were recorded.Result:After treatment,CD3,CD4and CD56in combined group were higher than those in SOX group,while CD8was lower than that in the SOX group (P<0.05).Compared with the SOX group,the levels of VEGF,CEA and CA199 were lower in the combined group (P<0.05).The disease control rate of the combined group was 76.56%,significantly higher than 57.14%of the SOX group (P<0.05).Platelet,hemoglobin and white blood cell counts in combined group were higher than those in the SOX group (P<0.05).The incidence of adverse reactions in the combined group was 9.38%,lower than 26.98%in the SOX group (P<0.05).Conclusion:For patients with advanced gastric cancer,Ubenimex Tablets with SOX regimen joint treatment can effectively improve the immune function and the level of serum tumor markers,can effectively control the disease progression,help reduce the side reaction of chemotherapy to produce at the same time,a lower risk adverse reactions,which can realize the improvement of prognosis,thus can be used as a clinical optimal method for the treatment of advanced gastric cancer.